ConforMIS, Inc. (CFMS) Receives “Hold” Rating from BTIG Research

BTIG Research reaffirmed their hold rating on shares of ConforMIS, Inc. (NASDAQ:CFMS) in a research report released on Thursday.

CFMS has been the subject of a number of other reports. Zacks Investment Research cut ConforMIS from a hold rating to a sell rating in a research report on Tuesday, July 11th. Oppenheimer Holdings, Inc. set a $6.00 price objective on ConforMIS and gave the stock a buy rating in a research report on Friday, August 4th. Deutsche Bank AG reaffirmed a hold rating and set a $5.00 price objective (down from $6.00) on shares of ConforMIS in a research report on Friday, August 4th. ValuEngine raised ConforMIS from a strong sell rating to a sell rating in a research report on Friday, September 1st. Finally, Canaccord Genuity decreased their price objective on ConforMIS from $8.00 to $6.00 and set a hold rating for the company in a research report on Friday, August 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. ConforMIS presently has a consensus rating of Hold and a consensus price target of $6.71.

ConforMIS (CFMS) traded up $0.17 during trading on Thursday, reaching $3.52. The company’s stock had a trading volume of 249,887 shares, compared to its average volume of 135,131. The company has a debt-to-equity ratio of 0.43, a quick ratio of 6.11 and a current ratio of 6.98.

ConforMIS (NASDAQ:CFMS) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. ConforMIS had a negative return on equity of 71.21% and a negative net margin of 72.70%. The company had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $17.55 million. During the same period last year, the firm earned ($0.31) EPS. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. equities analysts predict that ConforMIS will post -1.29 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ConforMIS, Inc. (CFMS) Receives “Hold” Rating from BTIG Research” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/11/04/conformis-inc-cfms-receives-hold-rating-from-btig-research.html.

Hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN raised its stake in shares of ConforMIS by 1.8% during the 1st quarter. Wells Fargo & Company MN now owns 53,930 shares of the medical instruments supplier’s stock worth $282,000 after buying an additional 935 shares in the last quarter. Platinum Investment Management Ltd. raised its stake in shares of ConforMIS by 23.6% during the 2nd quarter. Platinum Investment Management Ltd. now owns 335,156 shares of the medical instruments supplier’s stock worth $1,437,000 after buying an additional 63,900 shares in the last quarter. ARK Investment Management LLC raised its stake in shares of ConforMIS by 208.5% during the 2nd quarter. ARK Investment Management LLC now owns 192,378 shares of the medical instruments supplier’s stock worth $825,000 after buying an additional 130,009 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of ConforMIS by 1,313.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 148,147 shares of the medical instruments supplier’s stock worth $773,000 after buying an additional 137,667 shares in the last quarter. Finally, UBS Group AG raised its stake in shares of ConforMIS by 53.0% during the 1st quarter. UBS Group AG now owns 269,551 shares of the medical instruments supplier’s stock worth $1,407,000 after buying an additional 93,330 shares in the last quarter. 33.63% of the stock is owned by institutional investors and hedge funds.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

What are top analysts saying about ConforMIS Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ConforMIS Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit